New milestone in cardiac radioablation research
The STOPSTORM Consortium is proud to share the first results of the STOPSTORM.eu Registry Study, now published in the European Heart Journal. These results mark an important step forward for patients with refractory VT and highlight the potential of non-invasive treatment approaches. Read more.
The STOPSTORM Consortium is proud to share the first results of the STOPSTORM.eu Registry Study, now published in the European Heart Journal.
In this prospective multi-center study across 28 European centres, stereotactic arrhythmia radioablation (STAR) was associated with a substantial reduction in ventricular tachycardia (VT) burden in patients with otherwise limited treatment options.
Key findings:
• Median 80% reduction in VT episodes within 6 months after treatment
• 72% of patients free from ICD shocks after 6 months
• Favorable safety profile with no treatment-related deaths
These results mark an important step forward for patients with refractory VT and highlight the potential of non-invasive treatment approaches.
The STOPSTORM consortium continues to advance collaboration between cardiology, electrophysiology, and radiation oncology across Europe.
Read the full publication: https://doi.org/10.1093/eurheartj/ehag338
